Study: Alzheimer’s patients at higher risk for potentially avoidable hospital stays

Patients with Alzheimer’s disease or some form of related dementia were “significantly more likely” to be hospitalized for avoidable reasons, according to a new study published in the journal Alzheimer’s and Dementia.

Pei-Jung Lin, PhD, an assistant professor of medicine at Boston’s Tufts University School of Medicine, and her co-authors, compared Medicare claims data for beneficiaries with Alzheimer’s or related disorders with an equal number of non-Alzheimer’s patients drawn from a random Medicare sample.

The research found one in 10 Alzheimer’s patients had at least one avoidable hospital stay in 2013, with a total of more than 369,000 potentially avoidable stays being recorded. The study said this would add up to nearly $2.6 billion in Medicare bills in 2013. The costs of the avoidable stays were nearly even split between chronic conditions (53 percent of expenditures) and acute conditions (47 percent).

The results were reported at the Alzheimer’s Association International Conference in Toronto on July 25.

“The new results support that early Alzheimer's treatmenteven with today's first generation therapieshas significant potential to benefit the person with the disease, and the economy,” said Maria Carrillo, PhD, chief science officer of Alzheimer's Association.

Compared with beneficiaries without Alzheimer’s or dementia, those patients were found to be more at risk for potentially avoidable hospital stays for both short- and long-term complications of diabetes, as well as hypertension. Alzheimer’s patients were less likely to have avoidable stays for chronic obstructive pulmonary disease, asthma or heart failure.

Lin said Alzheimer’s and related disorders seems to make managing multiple conditions more difficult and expensive, and hospitals should find ways to optimize how comorbidities are handled.

“Case management programs for people with Alzheimer's and other dementias should involve strategies to reduce avoidable hospitalizations in order to improve patient outcomes and lower costs,” Lin said. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.